5398
慕康生醫
-0.05 (-0.35%)14.207成交張數142.50本益比1.36股價淨值比0.00%殖利率2026-09-16資料日期
綜合損益表公開資訊觀測站申報原值 · 年度(第 4 季累計) · 每一格 = 該期對去年同期的成長率
營業收入2025230年增 -3.6%
毛利率202537.1%最新一期
營業利益率20255.2%最新一期
每股盈餘20250.35年增 +66.7%
| 會計項目 | 走勢 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業收入合計 | – | +63.1% | -2.4% | -18.5% | -15.0% | -4.4% | -26.7% | -25.1% | +23.6% | -3.6% | |
| 營業成本合計 | – | +63.2% | +7.0% | -25.1% | -18.2% | -3.2% | -18.0% | -16.9% | -3.4% | -6.1% | |
| 營業毛利（毛損） | – | +62.7% | -22.1% | +0.4% | -8.1% | -6.9% | -44.1% | -49.1% | +152.5% | +0.9% | |
| 營業毛利（毛損）淨額 | – | +62.7% | -22.1% | +0.4% | -8.1% | -6.9% | -44.1% | -49.1% | +152.5% | +0.9% | |
| 推銷費用 | – | +389.1% | +20.6% | -0.4% | -19.1% | -19.6% | -16.5% | -3.9% | +1.8% | -32.2% | |
| 管理費用 | – | +44.9% | -26.6% | -37.4% | -18.5% | -15.6% | -2.6% | -11.5% | +17.4% | +24.8% | |
| 研究發展費用 | – | +75.7% | +28.4% | -26.5% | -6.3% | -14.3% | -42.3% | -10.8% | -51.7% | +57.0% | |
| 預期信用減損損失（利益） | – | – | – | -136.4% | – | +7.8% | -571.3% | – | +455.8% | -100.0% | |
| 營業費用合計 | – | +99.1% | -2.5% | -22.7% | -16.4% | -17.7% | -16.5% | -4.8% | +5.2% | -6.4% | |
| 營業利益（損失） | – | -131.3% | – | – | – | +93.7% | -152.6% | – | – | +94.5% | |
| 利息收入 | – | – | – | – | – | -30.1% | +6.9% | +100.4% | -9.1% | +49.1% | |
| 其他收入 | – | +30.5% | -44.0% | +238.0% | -70.8% | +5.1% | +77.3% | +8.5% | +76.4% | -7.3% | |
| 其他利益及損失淨額 | – | – | -249.7% | – | -115.8% | – | – | – | – | – | |
| 財務成本淨額 | – | +490.9% | -90.8% | +983.3% | +4.6% | +56.6% | +70.4% | +13.8% | +125.7% | -42.7% | |
| 營業外收入及支出合計 | – | – | -177.2% | – | -78.5% | -158.2% | – | +35.1% | -6.2% | +22.6% | |
| 稅前淨利（淨損） | – | +86.7% | -373.0% | – | -32.1% | +17.5% | -123.4% | – | – | +50.4% | |
| 所得稅費用（利益）合計 | – | +41.8% | -68.6% | -55.5% | +60.3% | +372.3% | -56.7% | -42.1% | +382.5% | +19.7% | |
| 繼續營業單位本期淨利（淨損） | – | +101.7% | -444.5% | – | -34.2% | -2.7% | -141.9% | – | – | +66.3% | |
| 本期淨利（淨損） | – | +101.7% | -444.5% | – | -34.2% | -2.7% | -141.9% | – | – | +66.3% | |
| 透過其他綜合損益按公允價值衡量之權益工具投資未實現評價損益 | – | – | – | – | +746.6% | -324.3% | – | – | – | -201.7% | |
| 不重分類至損益之項目： | – | – | – | – | +746.6% | -324.3% | – | – | – | -201.7% | |
| 國外營運機構財務報表換算之兌換差額 | – | – | – | – | – | – | – | -100.3% | – | -166.4% | |
| 後續可能重分類至損益之項目： | – | – | – | – | – | – | – | -100.3% | – | -166.4% | |
| 其他綜合損益（淨額） | – | – | -627.0% | – | – | -444.0% | – | – | – | -200.2% | |
| 本期綜合損益總額 | – | +299.2% | -472.4% | – | -23.6% | -56.0% | -300.9% | – | – | -135.9% | |
| 母公司業主（淨利∕損） | – | +101.7% | -444.5% | – | -34.2% | -2.7% | -141.9% | – | – | +66.3% | |
| 母公司業主（綜合損益） | – | +299.2% | -472.4% | – | -23.6% | -56.0% | -300.9% | – | – | -135.9% | |
| 基本每股盈餘 | – | +63.6% | -444.4% | – | -33.3% | -2.9% | -142.4% | – | – | +66.7% | |
| 稀釋每股盈餘 | – | – | -100.0% | – | -33.3% | -2.9% | -142.4% | – | – | +66.7% | |
| 銷貨收入 | – | +62.5% | -2.5% | -18.9% | -14.6% | – | – | – | – | – | |
| 銷貨收入淨額 | – | +62.5% | -2.5% | -18.9% | -14.6% | – | – | – | – | – | |
| 勞務收入淨額 | – | +175.0% | +14.9% | +21.9% | -42.9% | – | – | – | – | – | |
| 勞務收入 | – | +175.0% | +14.9% | +21.9% | -42.9% | – | – | – | – | – | |
| 銷貨成本 | – | +63.2% | +7.0% | -25.1% | -18.2% | – | – | – | – | – | |
| 繼續營業單位淨利（淨損） | – | +63.6% | -444.4% | – | -33.3% | – | – | – | – | – | |
| 備供出售金融資產未實現評價損益 | – | +491.7% | -100.0% | – | – | – | – | – | – | – |
金額為公司申報原值除以一千(百萬元,四捨五入),每股金額為元。年度為第 4 季的年初至今累計數。走勢條是歷史各期的相對大小,藍為正、綠為負。年增以去年同期為基期,基期非正數或變動超過十倍時不列。 權益變動表在申報資料分頁。